IFNA1 and dermatomyositis: The Janus kinase (JAK)- STAT signalling pathway is crucial in the IFN-mediated activation of cytokine receptors, and an inhibitor of JAK-1/3, tofacitinib, exhibited satisfactory effects on refractory DM as well as associated ILD [152-156].